 PF-06463922 is a selective, ATP competitive small molecule tyrosine kinase inhibitor TKI of the Anaplastic Lymphoma Kinase ALK positive ALK or ROS oncogene 1 ROS1 positive ROS1 receptor tyrosine kinases RTK that also potently inhibits ALK kinase domain mutations responsible for resistance to crizotinib. PF-06463922 is being developed as a novel anticancer agent for the treatment of patients with advanced ALK NSCLC or ROS1 NSCLC. 